Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services informed exchanges that its subsidiary, Optival Health Solutions Private Limited, received a 7-day suspension order for the Drug License of its store located in Sangvi, Pune, Maharashtra. The order was issued by the Asst. Commissioner & Licensing Authority, Food & Drug Administration, Pune, and was received on March 3, 2026, under Rule 65 of the Drugs and Cosmetics Act, 1940. The company has stated a potential revenue loss of approximately Rs 3.85 lakhs due to the temporary suspension. The matter is limited to a single store and falls under routine regulatory compliance disclosure.
The impact is minimal — it affects just one store for seven days with a small revenue loss of Rs 3.85 lakhs, which is immaterial relative to Medplus's overall operations. No significant effect on the stock is expected.